September Newsletter

Golden Helix Named on Inc 5000 List of Fastest-Growing Private Companies for 3rd Consecutive Year 

2021 End of Year Pricing Packages

By Delaina Hawkins
Senior Director of Operations & Marketing

We want to express our gratitude to all of our customers for their support with a promise not to increase prices in 2021. This is also a gesture we would like to extend to potential customers who are considering Golden Helix solutions through the variety of pricing packages that we have designed... Read More

Customizing VSClinical Reports with New Output Types

Customizing VSClinical Reports with New Output Types

By Gabe Rudy
VP of Product & Engineering

Golden Helix VSClinical provides a guided workflow interface for following the ACMG and AMP guidelines to evaluate variants and CNVs for NGS tests. The output of this work is most often a lab-specific clinical report. Since it was introduced, we have provided a powerful Word-based templating system to allow labs to customize reports to include specific content and branding...Read More

Updates to Somatic Variant Annotation and a New Way to Evaluate Fusions in VSClinical

Updates to Somatic Variant Annotation and a New Way to Evaluate Fusions in VSClinical

By Julia Love
Manager of Product Quality

Let's start things off by mentioning two annotation sources that are currently available in VarSeq 2.2.3 but were recently updated and released, COSMIC 94 and Golden Helix CancerKB. Golden Helix has been curating COSMIC annotation sources since COSMIC 88, all of which are available in VarSeq. The COSMIC annotation is broken up into 5 separate sources, Fusions, Hallmarks, Transcript Counts, Cancer Gene Census, and Mutations all of which are now available with the most up-to-date data from COSMIC and can be used to annotate VarSeq projects and in VSClinical... Read More

 

 

CEO Corner
New eBook: Clinical Variant Analysis for Cancer

We are close to finishing the final pieces of VSClinical's upcoming release. We are thrilled to share this information with everyone next week in the webcast "Advanced Scripting VSClinical Reports with Custom Integrations". This release was a significant engineering effort by our team. It has required extensive internal testing as well as valuable contributions from beta testers. I want to congratulate the Golden Helix team and testers for this achievement. Well done!

Upcoming Webcast

Advanced VSClinical Reports with Scripting and Custom Integrations

Oct. 6, 2021, 12pm EDT

Presented by Gabe Rudy, VP of Product & Engineering

The VarSeq Suite holds customization and extendibility as core values, allowing the powerful capabilities of variant analysis to be truly customized to the needs of a specific laboratory and NGS test. The new scripting and integration capabilities build on this tradition for the VSClinical workflows. We hope you can join us as we explore this topic in-depth in this webinar. 

Save Your Seat
Customer Success

Congratulations to all of our customers who have published this month! To highlight just a few:

The Aldehyde Dehydrogenase ALDH2*2 Allele, Associated with Alcohol Drinking Behaviour, Dates Back to Prehistoric Times - Kung-Hao Liang & colleagues, Taipei Veteran’s General Hospital / Published in Biomolecules

Targeted Molecular Characterization of External Auditory Canal Squamous Cell Carcinomas - Chad Brenner & colleagues, University of Michigan Medical School / Published in Laryngoscope Investigative Otolaryngology

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. Their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from NGS sequencers and microarrays. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.